Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Avoro Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 31, 2021
The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need.